{
    "clinical_study": {
        "@rank": "136139", 
        "arm_group": {
            "arm_group_label": "COL-1620", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this trial is to demonstrate the non-inferiority of the clinical\n      pregnancy rate per embryo transfer to the historical standard value in in-vitro\n      fertilization (IVF)/embryo transfer (ET) cycles in Japan (Japan Society of Obstetrics and\n      Gynecology [JSOG] 2009 registry data: 24.3 percent [%]). The secondary objectives of this\n      trial are to assess the biochemical pregnancy rate per ET, pharmacokinetics, and safety of\n      COL-1620."
        }, 
        "brief_title": "Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Luteal Hormone Supplementation in In-vitro Fertilization", 
            "Embryo Transfer"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese race\n\n          -  Woman with a history of infertility and in whom IVF/ET is indicated\n\n          -  The COS therapy is GnRH analogue (agonist or antagonist) in combination with a\n             FSH-containing preparation\n\n          -  Healthy premenopausal woman aged between 20 and 45 years (inclusive) and wishing to\n             conceive\n\n          -  Body mass index (BMI) of 17.0 to 25.0 kilogram per square meter (kg/m^2) (inclusive)\n\n          -  A negative pregnancy test (urinary beta-hCG) prior to starting COS\n\n          -  Normal cervical smear result (Papanicolaou [PAP] test: Negative for Intraepithelial\n             Lesion or Malignancy [NILM] or [Atypical Squamous Cells of Undetermined Significance\n             {ASC-US} and Human Papillomavirus {HPV} negative]) within 12 months prior to the date\n             of informed consent. If not available, a cervical smear and HPV test will be\n             performed as part of Screening\n\n          -  No clinically significant abnormal findings in the Screening hematology, biochemistry\n             and urinalysis parameters\n\n          -  Full comprehension of the study and voluntary written informed consent obtained in\n             writing prior to any trial-related activities\n\n        Exclusion Criteria:\n\n          -  History of recurrent pregnancy loss (defined as 3 or more previous spontaneous\n             abortions)\n\n          -  History of 3 or more consecutive cancelled or failed (no clinical pregnancy) IVF/ET\n             cycles\n\n          -  Abnormal hemorrhage of the reproductive tract of undetermined origin\n\n          -  Any contraindication to being pregnant and/or carrying a pregnancy to term (for\n             example, malformations of sexual organs or fibroid tumors of the uterus incompatible\n             with pregnancy)\n\n          -  Uterine myoma requiring treatment\n\n          -  Extra-uterine pregnancy within the last 3 months prior to the date of informed\n             consent\n\n          -  History or presence of intracranial tumor (for example, hypothalamic or pituitary\n             tumor)\n\n          -  Presence of or suspected gonadotropin- or estrogen-dependent malignancy (for example,\n             ovarian, uterine or mammary carcinoma)\n\n          -  Ovarian enlargement or cyst of unknown etiology\n\n          -  Breast-feeding or lactation\n\n          -  History of severe Ovarian Hyperstimulation Syndrome (OHSS) (Classification of OHSS\n             Severity, as per Japan Reproductive/Endocrine Working Group)\n\n          -  Known Human Immunodeficiency Virus (HIV)-positive status, or a history of or current\n             active infection with Hepatitis B or C\n\n          -  Known allergy or hypersensitivity to progesterone preparations or gonadotropin\n             preparations and/or their excipients, or any contraindication to receive medication\n             for controlled ovarian stimulation (for example, gonadotropin, GnRH analogues,\n             combined oral contraceptive pill, as appropriate)\n\n          -  History of or suspected alcohol or substance abuse within 5 years prior to the date\n             of informed consent\n\n          -  Clinically significant systemic disease (for example, insulin-dependent diabetes,\n             epilepsy, severe migraine, acute porphyria, hepatic, renal or cardiovascular disease,\n             severe corticosteroid-dependent asthma)\n\n          -  Active thrombophlebitis, thromboembolic disorder or cerebral apoplexy, or a history\n             of such conditions\n\n          -  Other significant disease that in the Investigator's or Sub-Investigator's opinion\n             would exclude the subject from the trial\n\n          -  Participation in another clinical trial within 3 months prior to the date of informed\n             consent or simultaneous participation in another clinical trial\n\n          -  Legal incapacity or limited legal capacity"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863680", 
            "org_study_id": "EMR200113_001"
        }, 
        "intervention": [
            {
                "arm_group_label": "COL-1620", 
                "description": "COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8% gel) will be administered by the vaginal route once daily, from the day of ovum pick-up (OPU) until Week 12, or until the confirmation of miscarriage or extra-uterine pregnancy.", 
                "intervention_name": "COL-1620", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "COL-1620", 
                "description": "Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for IVF/ET according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.", 
                "intervention_name": "Gonadotropin-releasing hormone (GnRH) analogue", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "COL-1620", 
                "description": "Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.", 
                "intervention_name": "Follicle-stimulating hormone (FSH)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "COL-1620", 
                "description": "Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.", 
                "intervention_name": "Human Chorionic Gonadotropin (hCG)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chorionic Gonadotropin", 
                "Hormones", 
                "Progesterone", 
                "Follicle Stimulating Hormone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Infertility", 
            "COL-1620", 
            "progesterone gel", 
            "Fertilization in Vitro", 
            "Embryo Transfer"
        ], 
        "lastchanged_date": "May 23, 2013", 
        "number_of_arms": "1", 
        "official_title": "Open-label, Single-arm, Multicenter Phase III Trial to Evaluate the Efficacy and Safety of COL-1620 8% Vaginal Progesterone Gel for Luteal Phase Support in In-vitro Fertilization and Embryo Transfer (IVF/ET) Cycles in Japanese Women", 
        "overall_contact": {
            "email": "service@merck.de", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of subjects with Clinical pregnancy per Embryo Transfer", 
            "safety_issue": "No", 
            "time_frame": "Week 5 post embryo transfer"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863680"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of subjects with Biochemical pregnancy per Embryo Transfer", 
                "safety_issue": "No", 
                "time_frame": "Week 5 post embryo transfer"
            }, 
            {
                "measure": "Serum progesterone level", 
                "safety_issue": "No", 
                "time_frame": "Day of human chorionic gonadotropin (hCG) administration and Day 14+/-3 post embryo transfer"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}